Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,DMAC,26014000,18786200,3120000,,-4193000,,-4200000,1148000,0,-4268000,-4268000,,,,,,7000,0,4268000,0,75000,,-4200000,-4200000,94925000,2081000,26014000,8000,28095000,10000,-68909000,-2000,7409000,2028000,-2000,174000,27921000,20098000,340000,1099000,696000.0,379000.0,667000.0,-1000.0,-39000.0,266000.0,-2388000.0,-38000.0,-3016000.0,5000.0,-5000.0,539000.0,-45000.0,,25893000,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.25,1630505151,-0.05000019,4.34,4.48,4.25,66217,-4.6703296,1.388,3.6319444,0.6180556,0.1701721,7.1320653,-2.8820653,-0.40409967,79841352,-2.8716216,3.0619597,15,America/New_York,EDT,False,False,USD,-0.91,us_market,DiaMedica Therapeutics Inc.,NCM,REGULAR,4,-1.1627951,4.25 - 4.48,4.3,4.32,4.36,18,22,finmb_4382397,NasdaqCM,DiaMedica Therapeutics Inc.,USD,317362,225366,1.25,0.41666666,3.0 - 10.88,-6.63,-0.609375,3.0,10.88,1542240000,1620244800,1620244800,0,1620244800,-0.784,-1.48,-14400000,2.39,,,10.88,3.0,3.6319,7.1321,317.36k,225.37k,18.79M,,16.41M,7.90%,34.94%,186.97k,1.92,1.07%,1.00%,156.75k,,,,,,0.00%,"Nov 14, 2018",,1:20,"Nov 14, 2018","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-42.73%,-73.10%,,,,,-12.68M,-12.29M,-0.7840,,27.51M,1.47,118k,0.45,13.77,1.39,-9.19M,-4.87M,Value,55447,Healthcare,10,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",Minneapolis,763 612 6755,MN,1577750400,United States,http://www.diamedica.com,86400,Two Carlson Parkway,Biotechnology,Suite 260
t-1,DMAC,29758000,18786200,2180000,,-3191000,,-3193000,1139000,0,-3319000,-3319000,,,,,,2000,0,3319000,0,128000,,-3193000,-3193000,94457000,1512000,29758000,13000,31270000,10000,-64709000,10000,9797000,1443000,10000,164000,31106000,20826000,335000,720000,-14000000.0,168000.0,-14000000.0,-1000.0,21189000.0,169000.0,4842000.0,-38000.0,-2347000.0,5000.0,-16000.0,520000.0,-45000.0,21190000.0,29663000,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.25,1630505151,-0.05000019,4.34,4.48,4.25,66217,-4.6703296,1.388,3.6319444,0.6180556,0.1701721,7.1320653,-2.8820653,-0.40409967,79841352,-2.8716216,3.0619597,15,America/New_York,EDT,False,False,USD,-0.91,us_market,DiaMedica Therapeutics Inc.,NCM,REGULAR,4,-1.1627951,4.25 - 4.48,4.3,4.32,4.36,18,22,finmb_4382397,NasdaqCM,DiaMedica Therapeutics Inc.,USD,317362,225366,1.25,0.41666666,3.0 - 10.88,-6.63,-0.609375,3.0,10.88,1542240000,1620244800,1620244800,0,1620244800,-0.784,-1.48,-14400000,2.39,,,10.88,3.0,3.6319,7.1321,317.36k,225.37k,18.79M,,16.41M,7.90%,34.94%,186.97k,1.92,1.07%,1.00%,156.75k,,,,,,0.00%,"Nov 14, 2018",,1:20,"Nov 14, 2018","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-42.73%,-73.10%,,,,,-12.68M,-12.29M,-0.7840,,27.51M,1.47,118k,0.45,13.77,1.39,-9.19M,-4.87M,Value,55447,Healthcare,10,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",Minneapolis,763 612 6755,MN,1577750400,United States,http://www.diamedica.com,86400,Two Carlson Parkway,Biotechnology,Suite 260
t-2,DMAC,11272000,18786200,1629000,,-2465000,,-2474000,1079000,0,-2708000,-2708000,,,,,,9000,0,2708000,0,243000,,-2474000,-2474000,72759000,1309000,11272000,23000,12581000,46000,-61516000,29000,4955000,1217000,29000,182000,12399000,6844000,319000,552000,2500000.0,108000.0,2500000.0,-1000.0,-1000.0,411000.0,1655000.0,-38000.0,-844000.0,5000.0,666000.0,440000.0,-45000.0,21190000.0,11182000,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.25,1630505151,-0.05000019,4.34,4.48,4.25,66217,-4.6703296,1.388,3.6319444,0.6180556,0.1701721,7.1320653,-2.8820653,-0.40409967,79841352,-2.8716216,3.0619597,15,America/New_York,EDT,False,False,USD,-0.91,us_market,DiaMedica Therapeutics Inc.,NCM,REGULAR,4,-1.1627951,4.25 - 4.48,4.3,4.32,4.36,18,22,finmb_4382397,NasdaqCM,DiaMedica Therapeutics Inc.,USD,317362,225366,1.25,0.41666666,3.0 - 10.88,-6.63,-0.609375,3.0,10.88,1542240000,1620244800,1620244800,0,1620244800,-0.784,-1.48,-14400000,2.39,,,10.88,3.0,3.6319,7.1321,317.36k,225.37k,18.79M,,16.41M,7.90%,34.94%,186.97k,1.92,1.07%,1.00%,156.75k,,,,,,0.00%,"Nov 14, 2018",,1:20,"Nov 14, 2018","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-42.73%,-73.10%,,,,,-12.68M,-12.29M,-0.7840,,27.51M,1.47,118k,0.45,13.77,1.39,-9.19M,-4.87M,Value,55447,Healthcare,10,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",Minneapolis,763 612 6755,MN,1577750400,United States,http://www.diamedica.com,86400,Two Carlson Parkway,Biotechnology,Suite 260
t-3,DMAC,13323000,18786200,1381000,,-2416000,,-2425000,1023000,0,-2404000,-2404000,,,,,,9000,0,2404000,0,-12000,,-2425000,-2425000,72323000,1042000,13323000,18000,14365000,195000,-59042000,42000,3300000,935000,42000,200000,14165000,9348000,985000,444000,-5299000.0,262000.0,-5301000.0,-2000.0,7696000.0,-1051000.0,-583000.0,-38000.0,-2978000.0,6000.0,-162000.0,392000.0,-2000.0,7698000.0,13230000,en-US,US,EQUITY,True,Nasdaq Real Time Price,4.25,1630505151,-0.05000019,4.34,4.48,4.25,66217,-4.6703296,1.388,3.6319444,0.6180556,0.1701721,7.1320653,-2.8820653,-0.40409967,79841352,-2.8716216,3.0619597,15,America/New_York,EDT,False,False,USD,-0.91,us_market,DiaMedica Therapeutics Inc.,NCM,REGULAR,4,-1.1627951,4.25 - 4.48,4.3,4.32,4.36,18,22,finmb_4382397,NasdaqCM,DiaMedica Therapeutics Inc.,USD,317362,225366,1.25,0.41666666,3.0 - 10.88,-6.63,-0.609375,3.0,10.88,1542240000,1620244800,1620244800,0,1620244800,-0.784,-1.48,-14400000,2.39,,,10.88,3.0,3.6319,7.1321,317.36k,225.37k,18.79M,,16.41M,7.90%,34.94%,186.97k,1.92,1.07%,1.00%,156.75k,,,,,,0.00%,"Nov 14, 2018",,1:20,"Nov 14, 2018","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-42.73%,-73.10%,,,,,-12.68M,-12.29M,-0.7840,,27.51M,1.47,118k,0.45,13.77,1.39,-9.19M,-4.87M,Value,55447,Healthcare,10,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.",Minneapolis,763 612 6755,MN,1577750400,United States,http://www.diamedica.com,86400,Two Carlson Parkway,Biotechnology,Suite 260
